Literature DB >> 2931452

Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma.

F Caligaris-Cappio, L Bergui, L Tesio, G Pizzolo, F Malavasi, M Chilosi, D Campana, B van Camp, G Janossy.   

Abstract

Precursors of plasma cells were studied in the bone marrow of 28 patients with multiple myeloma, plasma cell leukemia, and benign monoclonal gammopathy. Pre-B and B cell populations were analyzed with anti-B monoclonal antibodies corresponding to the clusters standardized at the Leucocyte Typing Workshops in Paris and Boston (CD9, CD10, CD19-22, CD24). In advanced forms of plasma cell malignancies, such as cases of multiple myeloma in stages II and III and of plasma cell leukemia, some cells of lymphoid morphology expressed common acute lymphoblastic leukemia antigen (CALLA, CD10) and HLA-DR, but contained no detectable terminal deoxynucleotidyl transferase enzyme. These CALLA+ cells were absent in benign monoclonal gammopathies. In multiple myeloma, the CALLA+ cells were negative for surface and cytoplasmic immunoglobulins (Ig), and, unlike CALLA+, terminal deoxynucleotidyl transferase (TdT+) pre-B cells in the normal bone marrow also failed to react with antibodies to B cell-associated antigens such as CD9, CD19, CD22, and CD24. The CALLA+, Ig- cells could be regarded as preplasmacytic since, after having been separated and stimulated with the phorbol ester 12-0-tetradecanoyl-phorbol-13 acetate in vitro, they transformed into plasma cells and synthesized the same heavy and light chains as myeloma cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2931452      PMCID: PMC424031          DOI: 10.1172/JCI112080

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  44 in total

1.  In vivo kinetic studies in human myeloma.

Authors:  A Pileri; R P Tarocco
Journal:  Haematologica       Date:  1974-03       Impact factor: 9.941

2.  Pre-B-cell leukemia. A new phenotype of childhood lymphoblastic leukemia.

Authors:  L B Vogler; W M Crist; D E Bockman; E R Pearl; A R Lawton; M D Cooper
Journal:  N Engl J Med       Date:  1978-04-20       Impact factor: 91.245

3.  Primary bioassay of human myeloma stem cells.

Authors:  A Hamburger; S E Salmon
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

4.  Characterization of a murine monoclonal antibody specific for human early lymphohemopoietic cells.

Authors:  F Malavasi; F Caligaris-Cappio; C Milanese; P Dellabona; P Richiardi; A O Carbonara
Journal:  Hum Immunol       Date:  1984-01       Impact factor: 2.850

5.  The changing face of myeloma.

Authors:  J R Durant; W E Barry; N Learner
Journal:  Lancet       Date:  1966-01-15       Impact factor: 79.321

6.  Monitoring myelomatosis.

Authors:  J R Hobbs
Journal:  Arch Intern Med       Date:  1975-01

7.  Multiple myeloma: development of plasma cell sarcoma during apparently successful chemotherapy.

Authors:  J M Holt; A H Robb-Smith
Journal:  J Clin Pathol       Date:  1973-09       Impact factor: 3.411

8.  A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

Authors:  B G Durie; S E Salmon
Journal:  Cancer       Date:  1975-09       Impact factor: 6.860

9.  Circulating tumor cells in murine myeloma.

Authors:  T F Warner; H L Moses; D S Fair; R G Krueger
Journal:  J Natl Cancer Inst       Date:  1977-04       Impact factor: 13.506

10.  Target cell in chronic myeloid leukaemia and its relationship to acute lymphoid leukaemia.

Authors:  G Janossy; M Roberts; M F Greaves
Journal:  Lancet       Date:  1976-11-13       Impact factor: 79.321

View more
  25 in total

Review 1.  Cancer stem cells in multiple myeloma.

Authors:  Nilanjan Ghosh; William Matsui
Journal:  Cancer Lett       Date:  2008-09-21       Impact factor: 8.679

2.  An analysis of myeloma plasma cell phenotype using antibodies defined at the IIIrd International Workshop on Human Leucocyte Differentiation Antigens.

Authors:  N Jackson; N R Ling; J Ball; E Bromidge; P D Nathan; I M Franklin
Journal:  Clin Exp Immunol       Date:  1988-06       Impact factor: 4.330

3.  CD19-positive antibody-secreting cells provide immune memory.

Authors:  C J Groves; J Carrell; R Grady; B Rajan; C A Morehouse; R Halpin; J Wang; J Wu; Y Shrestha; R Rayanki; R Kolbeck; Y Wang; R Herbst
Journal:  Blood Adv       Date:  2018-11-27

4.  Normal and neoplastic plasma cell membrane phenotype: studies with new monoclonal antibodies.

Authors:  P L Tazzari; M Gobbi; A Dinota; A Bontadini; G Grassi; C Cerato; M Cavo; S Pileri; F Caligaris-Cappio; S Tura
Journal:  Clin Exp Immunol       Date:  1987-10       Impact factor: 4.330

5.  Novel type of proliferating lymphoplasmacytoid cell with a characteristic spotted immunofluorescence pattern.

Authors:  H M Lokhorst; S E Boom; B J Bast; P J Peters; T F Tedder; J Gerdes; E Petersen; R E Ballieux
Journal:  J Clin Invest       Date:  1987-05       Impact factor: 14.808

Review 6.  Cancer stem cells: controversies in multiple myeloma.

Authors:  Sarah K Brennan; William Matsui
Journal:  J Mol Med (Berl)       Date:  2009-09-17       Impact factor: 4.599

7.  Immunophenotypic and genotypic characterisation of multiple myelomas with adverse prognosis characterised by immunohistological expression of the T cell related antigen CD45RO (UCHL-1).

Authors:  D M Menke; H P Horny; H Griesser; E J Atkinson; E Kaiserling; R A Kyle
Journal:  J Clin Pathol       Date:  1998-06       Impact factor: 3.411

Review 8.  Multiple myeloma cancer stem cells.

Authors:  Carol Ann Huff; William Matsui
Journal:  J Clin Oncol       Date:  2008-06-10       Impact factor: 44.544

9.  Establishment of five human myeloma cell lines.

Authors:  M Namba; T Ohtsuki; M Mori; A Togawa; H Wada; T Sugihara; Y Yawata; T Kimoto
Journal:  In Vitro Cell Dev Biol       Date:  1989-08

10.  Tumour formation by single fibroblast growth factor receptor 3-positive rhabdomyosarcoma-initiating cells.

Authors:  M Hirotsu; T Setoguchi; Y Matsunoshita; H Sasaki; H Nagao; H Gao; K Sugimura; S Komiya
Journal:  Br J Cancer       Date:  2009-11-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.